Coya Therapeutics Announces $10.0 Million Private Placement
22 Ottobre 2024 - 3:00PM
Business Wire
Majority of investors in offering are existing
institutional stockholders of Coya
Coya Therapeutics, Inc. (Nasdaq:COYA) (“Coya” or the “Company”),
a clinical-stage biotechnology company developing biologics and
cell therapies intended to enhance the function of regulatory T
cells (“Tregs”), announced today that it has entered into
definitive securities purchase agreements for the purchase and sale
of an aggregate of 1,379,314 shares of its common stock in a
private placement at a price of $7.25 per share. The offering is
expected to close on or about October 23, 2024, subject to the
satisfaction of customary closing conditions. The majority of
investors in the offering are existing institutional stockholders
of the Company.
BTIG, LLC is acting as the lead placement agent and Allele
Capital Partners, LLC, through its executing broker-dealer,
Wilmington Capital Securities, LLC, and Chardan Capital Markets LLC
are acting as co-placement agents for the offering.
The gross proceeds to the Company from the private placement are
expected to be approximately $10.0 million, before deducting the
placement agents’ fees and other offering expenses payable by the
Company. The Company intends to use the net proceeds for general
corporate purposes, including general and administrative expenses,
working capital and to support preclinical, clinical and regulatory
activities related to the Company’s existing and future product
candidate pipeline.
The offer and sale of the securities described above are being
offered in a private placement under Section 4(a)(2) of the
Securities Act of 1933, as amended (the “Act”), and/or Regulation D
promulgated thereunder and have not been registered under the Act,
or applicable state securities laws. Accordingly, the securities
issued in the private placement may not be offered or sold in the
United States except pursuant to an effective registration
statement or an applicable exemption from the registration
requirements of the Act and such applicable state securities
laws.
The Company has agreed to file a registration statement with the
Securities and Exchange Commission (“SEC”) covering the resale of
the securities to be issued in the offering no later than 30 days
following the date of the definitive agreements and to have the
registration statement declared effective no later than 75 days
following the date of the definitive agreements in the event of a
“full review” by the SEC.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system.
Forward Looking Statements
This release contains “forward-looking statements” made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements are typically preceded by
words such as “may,” “can,” “anticipate,” “assume,” “should,”
“indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,”
“estimate,” “continue,” “plan,” “point to,” “project,” “predict,”
“could,” “intend,” “target,” “potential,” “will,” or similar words
and expressions of the future. These forward-looking statements
reflect management’s current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct or that those goals will be
achieved, and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, risks associated with
market conditions and the satisfaction of customary closing
conditions related to the offering and uncertainties related to the
offering and the use of proceeds from the offering. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the Company’s business in
general, please refer to the Company’s Form 10-K for the year ended
December 31, 2023 and Forms 10-Q for the quarters ended March 31,
2024, and June 30, 2024.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241022281329/en/
Investor Contact David
Snyder david@coyatherapeutics.com
CORE IR Bret Shapiro brets@coreir.com 561-479-8566
Media Contacts For Coya
Therapeutics: Kati Waldenburg media@coyatherapeutics.com
212-655-0924
Grafico Azioni Coya Therapeutics (NASDAQ:COYA)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Coya Therapeutics (NASDAQ:COYA)
Storico
Da Mar 2024 a Mar 2025